Hoth rises as preclinical data shows fatty liver drug outperforms semaglutide

Rocket One

14/04/2026 12:20

** Shares of biotech firm Hoth Therapeutics HOTH.O rise 50% to $0.76 premarket

** Co says its experimental drug GDNF showed promising preclinical results in metabolic-associated fatty liver disease, a condition marked by excess fat buildup in the liver that can lead to scarring and liver failure

** Says the study showed GDNF reduced activity of a gene linked to making fat in the liver and increased activity of a gene tied to burning fat

** Says the drug was more effective than obesity drug semaglutide in the preclinical model

** Adds GDNF targets underlying liver metabolism rather than weight loss alone and could treat fatty liver disease and obesity

** As of last close, stock down ~48% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))